This article is more than 5 years old. Information may no longer be current.
ACIP recommends addition of 4-strain influenza vaccine
Click Here to Manage Email Alerts
The CDC’s Advisory Committee on Immunization Practices voted unanimously, 13-0, to recommend addition of a four-strain influenza vaccine to the table of available vaccines, modification of the egg allergy algorithm to include recombinant hemagglutinin influenza vaccine and a trivalent formation, and language to address those with no history of egg allergy exposure but questionable allergy testing, according to presenters at the meeting.
The four-strain influenza vaccine (Fluzone Quadrivalent, Sanofi-Pasteur) includes two A strains and two B strains and is licensed for use in children aged 6 months and older, adolescents and adults.
This will be the first influenza season that quadrivalent vaccines are available.
The modification of the egg allergy algorithm includes offering the recombinant influenza vaccine to those with egg allergies who have hives and also for those with symptoms other than hives.
Language addressing those with no history of egg allergy exposure recommends that those with questionable allergy testing consult a physician with expertise in the management of allergies before vaccination.
According to Lisa Grohskopf, MD, MPH, of the CDC’s Influenza Division, some United States abbreviations also have been revised to refer to currently available vaccines. The abbreviation for trivalent influenza vaccine has been changed to inactivated influenza vaccine (IIV). In the upcoming influenza season, IIV classes will include egg-based and cell culture-based trivalent inactivate infleunza vaccine (IIV3) and egg-based quadrivalent inactivated influenza vaccine (IIV4). Recombinant hemagglutinin influenza vaccine (RIV) will be available as a trivalent formation (RIV3). Live-attenuated influenza vaccine will be available as a quadrivalent formulation (LAIV4).
Vaccines will include the A/California/7/2009(H1N1) pdm09-like virus, A(H3N2) virus and a B/Massachusetts/2/2012-like (B/Yamagata lineage) virus and B/Brisbane/60/2008-like (B/Victoria lineage) virus.